Janssen HLA - Search Results

1

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.

Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA; Hepatitis B Research Network. Terrault NA, et al. Among authors: janssen hla. Am J Gastroenterol. 2023 Jul 1;118(7):1214-1225. doi: 10.14309/ajg.0000000000002125. Epub 2022 Dec 23. Am J Gastroenterol. 2023. PMID: 36599136 Clinical Trial.

2

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Am J Gastroenterol. 2006 Feb;101(2):297-303. doi: 10.1111/j.1572-0241.2006.00418.x. Am J Gastroenterol. 2006. PMID: 16454834 Clinical Trial.

3

Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.

Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Am J Gastroenterol. 2006 Nov;101(11):2523-9. doi: 10.1111/j.1572-0241.2006.00812.x. Epub 2006 Oct 4. Am J Gastroenterol. 2006. PMID: 17029610 Clinical Trial.

4

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Buster EH, et al. Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15. Gastroenterology. 2008. PMID: 18585385 Clinical Trial.

5

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.

Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL. Buster EH, et al. Am J Gastroenterol. 2009 Oct;104(10):2449-57. doi: 10.1038/ajg.2009.371. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584831 Clinical Trial.

6

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Buster EH, et al. Gastroenterology. 2009 Dec;137(6):2002-9. doi: 10.1053/j.gastro.2009.08.061. Epub 2009 Sep 6. Gastroenterology. 2009. PMID: 19737568

7

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Reijnders JG, et al. Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059. Epub 2010 Apr 8. Gastroenterology. 2010. PMID: 20381492

8

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. Rijckborst V, et al. Am J Gastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May 11. Am J Gastroenterol. 2010. PMID: 20461068 Clinical Trial.

9

Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.

Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network; Hepatitis B Research Network. Ghany MG, et al. Clin Gastroenterol Hepatol. 2015 Jan;13(1):183-92. doi: 10.1016/j.cgh.2014.06.028. Epub 2014 Jul 8. Clin Gastroenterol Hepatol. 2015. PMID: 25010003 Free PMC article.

10

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.

Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL. Chi H, et al. Aliment Pharmacol Ther. 2015 May;41(9):867-76. doi: 10.1111/apt.13150. Epub 2015 Mar 5. Aliment Pharmacol Ther. 2015. PMID: 25752878 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page